LeMaitre Vascular, Inc. (NASDAQ:LMAT) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) have been assigned a consensus recommendation of “Moderate Buy” from the eight analysts that are covering the firm, Marketbeat Ratings reports. Four equities research analysts have rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $100.20.

A number of equities research analysts recently issued reports on LMAT shares. Barrington Research reiterated an “outperform” rating and issued a $95.00 price objective on shares of LeMaitre Vascular in a research report on Wednesday, October 15th. Wells Fargo & Company lowered their price target on LeMaitre Vascular from $97.00 to $93.00 and set an “equal weight” rating on the stock in a report on Friday, November 7th. Cantor Fitzgerald reiterated a “neutral” rating and set a $95.00 price target on shares of LeMaitre Vascular in a research report on Monday, November 10th. Roth Capital restated a “buy” rating and issued a $108.00 price objective on shares of LeMaitre Vascular in a research report on Wednesday, November 5th. Finally, Zacks Research raised shares of LeMaitre Vascular from a “hold” rating to a “strong-buy” rating in a research note on Friday, November 7th.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in LeMaitre Vascular during the first quarter valued at about $728,000. Avantax Advisory Services Inc. increased its position in shares of LeMaitre Vascular by 1.5% during the 1st quarter. Avantax Advisory Services Inc. now owns 15,035 shares of the medical instruments supplier’s stock valued at $1,261,000 after purchasing an additional 229 shares during the last quarter. Cetera Investment Advisers raised its holdings in shares of LeMaitre Vascular by 209.6% during the 1st quarter. Cetera Investment Advisers now owns 8,522 shares of the medical instruments supplier’s stock valued at $715,000 after buying an additional 5,769 shares in the last quarter. Federated Hermes Inc. lifted its position in LeMaitre Vascular by 1.3% in the 1st quarter. Federated Hermes Inc. now owns 39,504 shares of the medical instruments supplier’s stock worth $3,314,000 after buying an additional 518 shares during the last quarter. Finally, Vestcor Inc boosted its stake in LeMaitre Vascular by 108.0% in the first quarter. Vestcor Inc now owns 3,079 shares of the medical instruments supplier’s stock worth $258,000 after buying an additional 1,599 shares in the last quarter. Institutional investors own 84.64% of the company’s stock.

LeMaitre Vascular Trading Up 4.1%

Shares of LeMaitre Vascular stock opened at $87.93 on Monday. The company’s 50-day moving average price is $88.13 and its 200-day moving average price is $87.05. The company has a current ratio of 13.96, a quick ratio of 11.74 and a debt-to-equity ratio of 0.46. LeMaitre Vascular has a 12-month low of $71.42 and a 12-month high of $109.58. The company has a market cap of $1.99 billion, a price-to-earnings ratio of 42.68, a PEG ratio of 2.29 and a beta of 0.77.

LeMaitre Vascular (NASDAQ:LMAT) last issued its quarterly earnings data on Thursday, November 6th. The medical instruments supplier reported $0.62 EPS for the quarter, beating the consensus estimate of $0.57 by $0.05. LeMaitre Vascular had a net margin of 20.08% and a return on equity of 13.67%. The company had revenue of $61.05 million during the quarter, compared to analysts’ expectations of $62.18 million. During the same quarter in the previous year, the company earned $0.49 earnings per share. LeMaitre Vascular’s revenue for the quarter was up 11.4% on a year-over-year basis. LeMaitre Vascular has set its FY 2025 guidance at 2.480-2.530 EPS. Q4 2025 guidance at 0.640-0.690 EPS. On average, equities analysts expect that LeMaitre Vascular will post 1.94 earnings per share for the current fiscal year.

LeMaitre Vascular Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, December 4th. Stockholders of record on Thursday, November 20th will be given a dividend of $0.20 per share. The ex-dividend date is Thursday, November 20th. This represents a $0.80 annualized dividend and a dividend yield of 0.9%. LeMaitre Vascular’s dividend payout ratio (DPR) is 34.48%.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.